All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Primary endpoint met in InMIND trial of tafasitamab in patients with R/R FL
On August 15, 2024, it was announced that the phase III randomized, double-blind, placebo-controlled InMIND trial (NCT04680052), investigating tafasitamab, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with lenalidomide alone as an add-on to rituximab for patients with relapsed/refractory (R/R) follicular lymphoma (FL) met its primary endpoint of progression-free survival (PFS) in patients with R/R FL. In addition, no with no new safety signals were reported.
These results suggest that tafasitamab, in combination with lenalidomide and rituximab, has the potential to improve outcomes in patients with R/R FL whose disease has progressed after at least one prior therapy.
Tafasitamab has previously received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and approval from the U.S. Food and Drug Administration (FDA) for use in combination with lenalidomide to treat adult patients with R/R diffuse large B‑cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?
